GlassScriptPhysician profile
Alison Nicole Daugherty
NPI 1013519685
$2,780.05
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,606 · 2022: $1,029 · 2023: $91.16 · 2024: $54.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $145.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $450.25 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.84 | 2021-2022 | |
| Glaxosmithkline, LLC. | $314.66 | 2021-2024 | Shingrix, Arexvy |
| Abbvie INC. | $261.86 | 2021-2023 | |
| Pfizer INC. | $211.16 | 2021-2022 | |
| Lilly USA, LLC | $155.43 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $133.59 | 2021-2022 | |
| Radius Health, INC. | $133.51 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $101.51 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $79.88 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $77.48 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $75.11 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.61 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $34.13 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.86 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $32.16 | 2021 | |
| Philips North America LLC | $27.32 | 2021 | |
| Biogen, INC. | $26.15 | 2021 | |
| Qiagen, LLC | $23.21 | 2021 | |
| Avanir Pharmaceuticals, INC. | $22.55 | 2022 | |
| Sun Pharmaceutical Industries INC. | $22.53 | 2021 | |
| Insulet Corporation | $22.45 | 2021 | |
| Novartis Pharmaceuticals Corporation | $22.15 | 2021 | |
| Sumitomo Pharma America, INC. | $22.07 | 2024 | Gemtesa |
| Amgen INC. | $21.89 | 2021 | |
| Novo Nordisk INC | $18.04 | 2021 | |
| Nestle Healthcare Nutrition INC. | $16.69 | 2022 | |
| Acerus Pharmaceuticals Corporation | $13.78 | 2021 | |
| Ethicon US, LLC | $13.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Daugherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.